

# Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal

Van Morris<sup>1</sup>, Xiayu Rao<sup>2</sup>, Curtis Pickering<sup>3</sup>, Wai Chin Foo<sup>4</sup>, Asif Rashid<sup>4</sup>, Karina Eterovic<sup>5</sup>, Taebeom Kim<sup>2</sup>, Ken Chen<sup>2</sup>, Jing Wang<sup>2</sup>, Kenna Shaw<sup>6</sup>, and Cathy Eng<sup>1</sup>



## Abstract

Squamous cell carcinoma of the anal canal (SCCA) is a rare gastrointestinal malignancy with an increasing annual incidence globally. The majority of cases are linked to prior infection with the human papillomavirus (HPV). For patients with metastatic SCCA, no consensus standard treatment exists. Identification of relevant targeted agents as novel therapeutic approaches for metastatic SCCA has been limited by a lack of comprehensive molecular profiling. We performed whole-exome sequencing on tumor-normal pairs from 24 patients with metastatic SCCA. Tumor tissue from 17 additional patients was analyzed using a 263-gene panel as a validation cohort. Gene expression profiling was performed on available frozen tissue to assess for differential expression patterns. Based on these findings, patient-derived xenograft (PDX) models of SCCA were generated to test targeted therapies against PI3K and EGFR. Despite a low mutation burden,

mutations in *PIK3CA*, *MLL2*, and *MLL3* were among the most commonly mutated genes. An association between *TP53* mutations and HPV-negative SCCA tumors was observed. Gene expression analysis suggested distinct tumor subpopulations harboring *PIK3CA* mutations and for which HPV had integrated into the host genome. *In vivo* studies demonstrated improvement with anti-EGFR treatment. Gene mutation frequencies, tumor mutation burden, and gene expression patterns for metastatic SCCA appear similar to other HPV-associated malignancies.

**Implications:** This first comprehensive genomic characterization for patients with metastatic SCCA provides further rationale for the integration of SCCA into the development of novel targeted therapies across HPV-related cancers. *Mol Cancer Res*; 15(11); 1542–50. ©2017 AACR.

## Introduction

Squamous cell carcinoma of the anal canal (SCCA) represents approximately 2% of all gastrointestinal malignancies (1), with a global incidence that continues to increase annually (2). While patients afflicted with SCCA who present with locoregional disease are generally offered chemoradiation (3, 4), approximately 25% of these patients will relapse and/or develop distant metastases (5, 6). Median overall survival for metastatic SCCA is estimated between 15 and 20 months (7), and patients are treated most commonly with standard cytotoxic doublet chemotherapy regimens (8–10).

Human papillomavirus (HPV) has been linked to 80% to 95% of patients with SCCA and is regarded to be the seminal driver for oncogenesis (11–14). To date, no targeted therapies have been prospectively proven to be effective for patients with metastatic SCCA based on a particular genomic abnormality. Off label, reports of targeted therapies against EGFR have been described in the management of metastatic SCCA (15, 16), an approach extrapolated from success in treating other HPV-associated metastatic malignancies (i.e., advanced squamous cell cancer of the head/neck; ref. 17).

Recently, targeted gene panels have provided insight into genomic features of patients with anal cancer across all stages of disease (18, 19). Comprehensive whole-exome sequencing of SCCA has never been reported for patients with metastatic anal cancer. Here, we sought to describe the genomic landscape for SCCA by analyzing specimens from 41 patients with metastatic SCCA at our institution and to correlate these findings with clinical and pathologic features.

## Materials and Methods

### Collection of patient samples

The MD Anderson patient databases were searched for patients who were diagnosed with metastatic SCCA between August 2002 and August 2015 and who consented to an IRB-approved protocol for retrospective analysis of archival tissue. Patients with adenocarcinoma of the anal canal or of the rectum were excluded, as were patients with nonmetastatic squamous cell carcinoma the anal canal. The presence of HPV was tested by assessment of p16

<sup>1</sup>Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>2</sup>Bioinformatics and Comp Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>3</sup>Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>4</sup>Pathology Admin, The University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>5</sup>Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>6</sup>Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

**Note:** Supplementary data for this article are available at Molecular Cancer Research Online (<http://mcr.aacrjournals.org/>).

**Corresponding Author:** Cathy Eng, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030. Phone: 713-745-8146; Fax: 713-794-1873; E-mail: Ceng@mdanderson.org

**doi:** 10.1158/1541-7786.MCR-17-0060

©2017 American Association for Cancer Research.

expression by immunohistochemistry or detection of HPV DNA by *in situ* hybridization.

#### DNA sequencing and copy number analysis

We performed whole-exome sequencing using samples from 24 patients with paired tumor and normal tissue to identify somatic mutations present in metastatic SCCA. Here, nine patients had normal tissue derived from a specimen with no known tumor present that was available in the institutional tissue bank and was confirmed by a collaborating pathologist. We ensured that adjacent, nonaffected anorectal tissue was not used as a normal control in order to minimize the field effects of HPV on analysis of nontumor tissue. For the remaining 15 patients for whom no frozen archival normal tissue was available, peripheral blood mononuclear cells (PBMC) were utilized for the normal control. Targeted mutation profiling using a 263-gene panel (Supplementary Fig. S1) was performed on a validation cohort of an additional 17 patients with only tumor tissue available. DNA was extracted from archived fixed-formalin, paraffin-embedded tumor tissue (see Supplementary Methods for further details on protocol for sequencing). To generate the lollipop diagrams with these data, the cBioPortal web tool, MutationMapper, was used ([http://www.cbioportal.org/public-portal/mutation\\_mapper.jsp](http://www.cbioportal.org/public-portal/mutation_mapper.jsp)). To explore for any association between gene mutation or clinicopathologic feature and survival, we performed multivariate analyses by conducting log-rank tests for categorical variables and the Cox proportional hazards model for continuous variables to correlate each variable to survival outcome. The Benjamini–Hochberg correction was applied to adjust for multiple testing. Kaplan–Meier survival curves were generated for any significant genes or clinical variables with an adjusted *P* value less than 0.05. To compare mutation frequencies among various squamous cell tumor types, the number of mutations detected per megabase of nucleotides examined during sequencing was calculated for each patient. A public database ([www.cbioportal.org](http://www.cbioportal.org)) was accessed to obtain these data for the non-SCCA tumor types not sequenced in our study. Mean values in mutation frequency for SCCA relative to other tumor types were compared using an independent *t* test adjusted with a Bonferroni correction. Copy number alterations were characterized as "amplified" for  $\geq 2.5$  copies for a given gene, according to methods previously described (20).

#### Gene expression profiling

RNA was isolated and sequenced from archived frozen specimens of patients at our institution (see Supplementary Methods for further details). We applied a Trimmed Mean of M-values method to normalize the count data. To examine relative similarities of the samples, we applied a principal component analysis (PCA) as well as a hierarchical clustering algorithm. The data analyses were performed using R, a publicly available statistical computing tool (<http://www.r-project.org/>) and Bioconductor packages (<http://www.bioconductor.org/>). Because no predetermined groups based on lack of historical information were available, the most variable genes, as measured by median absolute deviation based on gene expression, were selected for further analysis, from which we were able to classify samples into subtypes by evaluation of clustering, PCA plots, and correlation heatmaps. To determine patterns of HPV integration, a reference genome featuring a hybrid genome that combines selected virus

genomes, including HPV6, HPV16, HPV18, HPV33, HPV35, HPV45, and HPV56, was used with the VirusSeq pipeline for the HPV integration analysis as previously described (21).

#### Patient-derived xenograft studies

A tumor collected under an IRB-approved protocol from a freshly resected liver metastasis from a separate patient with SCCA (independent of the 41 sequenced patients) was implanted into the subcutaneous flank of a female, NOD-SCID-gamma mouse to create a patient-derived xenograft in which targeted therapies could be tested. The tumor was sequenced by targeted polymerase chain for mutations in *KRAS* (codons 12, 13, 61), *NRAS* (codons 12, 13, 61), *BRAF* (exon 15), *EGFR* (exons 18–21), and *PIK3CA* (exons 9 and 20). Once established, this xenograft tumor was expanded into a second generation of mice in two separate experiments. In the first, 7 mice per arm were randomized into an untreated control group or into a group that received the oral p110 $\alpha$  subunit-specific PI3K inhibitor BYL719 (Selleck Chemicals) at a dose of 35 mg/kg body weight daily. Due to lower rates of tumor establishing in the mouse when treated, four mice per arm were treated either as a control or with BYL719. In a second experiment, 10 mice per arm were randomized and treated twice weekly intraperitoneal injections of the chimeric anti-EGFR monoclonal antibody cetuximab (Bristol-Myers Squibb) at a dose of 30 mg/kg body weight or control solution. Tumor sizes were measured twice weekly for 35 days in the BYL719 experiment and for 28 days in the cetuximab experiment. At that time, mean tumor volumes each of the experimental and control groups were calculated and compared with one another for each of the two separate studies with a Fisher *t* test.

## Results

#### Mutation frequency/patient characteristics

Table 1 details the demographic characteristics of these patients with unresectable/metastatic SCCA. The median age at diagnosis of metastatic disease was 57 years (interquartile range, 49–60 years). The majority of patients (63%) had been initially diagnosed with locoregional disease which later recurred/metastasized after definitive chemoradiation. The liver was the most

**Table 1.** Patient demographics

Median age at diagnosis	57 years (interquartile range, 49–60)
Stage at diagnosis (%)	
II	14 (34)
III	12 (29)
IV	15 (37)
Gender (%)	
Female	33 (80)
Male	8 (20)
Ethnicity (%)	
Caucasian	39 (95)
African-American	2 (5)
HIV-positive (%)	3 (7)
Tumor differentiation (%)	
Well differentiated	1 (2)
Moderately differentiated	13 (32)
Poorly differentiated	27 (66)
Metastatic site (%)	
Liver	21 (51)
Lung	19 (46)
Lymph node	17 (41)
Local (unresectable) recurrence	15 (37)

common site for distant spread. HPV was detected in 16 of 18 tested tumors that underwent whole-exome sequencing. Most tumors (66%) were poorly differentiated.

### Genomic sequencing

For the 24 specimens that underwent whole-exome sequencing, the mean depth of coverage for sequencing was 128 (inter-quartile range, 98–158). As seen in Fig. 1, *PIK3CA* was the most commonly mutated gene in the cohort for which the entire exome was sequenced, present in 7 of 24 (29%) tumors. All of the mutations were located in the exon 2 and 4 hotspots (Fig. 2A) known to generate oncogenic activity of PIK3CA/mTOR signaling (22). Missense mutations of *RRBP1* were likewise present in 7 patients with metastatic anal cancer. These mutations all localized to the same region of the *RRBP1* gene (Supplementary Fig. S2). Other genes mutated in 2 or greater of the 24 sequenced tumors are listed in Fig. 1. *MLL3* and *MLL2* were mutated in 25% and 21% of tumors, respectively. In addition, genes important to cell-cycle dysregulation (*CNTRL*), DNA damage repair (*TP53*, *HUWE1*), chromatin remodeling (*EP300*), cell differentiation (*FLG*, *PTK2*), and activation of Wnt/ $\beta$ -catenin signaling (*FAM123B*) were all present in multiple tumors.


Figure 2 reveals the results of copy number assessment in the 24 cases which underwent whole-exome sequencing. *CCDC39* and *PIK3CA* were the most commonly amplified genes, noted in 20 of 24 cases (83%). Six of the 7 *PIK3CA* mutated tumors featured a *PIK3CA* amplification, and one had no detectable amplification. In sum, 21 of 24 tumors (88%) had an activating mutation and/or gene amplification of *PIK3CA*. Genes critical to signaling of the

MAPK pathway like *KRAS*, *NRAS*, and *EGFR* were not as commonly amplified.

Of the 17 tumors tested with the 263-gene panel of the validation set, the most commonly mutated genes were *MLL3* (39%), *PIK3CA* (28%), *TP53* (28%), *MLL2* (22%), and *EP300* (22%). These genes were among the most frequently mutated among the independent set of tumors analyzed in the orthogonal whole-exome cohort. Table 2 shows the pooled frequencies of the most common genes detected between the two sets. For the entire panel of 41 patients, *MLL3* (32%) and *PIK3CA* (29%) were the most commonly mutated genes for these patients with unresectable SCCA. Notably, *KRAS*, *NRAS*, *BRAF*, and *EGFR* mutations were not common, detected in <5% of all patients.


Figure 3A shows a median 2.5 somatic mutations/Mb detected across the entire exome (range, 0.1–6 mutations/Mb). The median number of mutations/Mb is similar to what has been seen from publicly available data for cervical cancer and HPV-positive head/neck cancer, and lower than squamous cell cancer of the lung ( $P < 0.001$ ; refs. 23–25). In addition, when analyzed according to the prevalence of specific nucleotide substitution, C>T substitutions were the most common, accounting for over half of all mutations detected (Fig. 3B).

Next, various clinicopathologic characteristics were analyzed for a correlation with various gene aberrations (Fig. 4). HPV status was tested in 18 of 24 tumors that underwent whole-exome sequencing (16 were HPV<sup>+</sup>; 2 were HPV<sup>-</sup>). *TP53* mutations were present in both of the HPV-negative tumors and were more likely to be associated with the absence of HPV relative to HPV-positive tumors [odds ratio (OR) 52,  $P = 0.03$ ]. Mutation frequency was



**Figure 1.** Mutation frequencies of the most commonly mutated genes from 24 SCCA tumors which underwent whole exome sequencing.

**Figure 2.** Copy number analysis of frequent and actionable genes for 24 SCCA tumors which underwent whole exome sequencing: no amplification or deletion (peach), amplification only (red), deletion only (orange), and amplification and deletion (blue).



similar in the HPV-positive cohort [mean mutations/Mb with standard deviation (SD),  $2.7 \pm 2.1$ ] relative to the HPV-negative tumors ( $2.0 \pm 0.89$ ), although no formal statistical characterization was performed due to the small number of HPV-negative tumors available for analysis. The median survival from the time of diagnosis of metastatic disease was 4.3 years for the pooled population of 42 patients. Using a multivariate analysis, being HIV-negative ( $P < 0.001$ ), and of female gender ( $P = 0.01$ ) were associated with prolonged survival. However, no mutations for any gene were noted to associate with survival.

**RNA profiling**

Ten patients had fresh frozen tumor available for gene expression profiling. The top 200 most variably expressed genes for expression were clustered to generate the heatmap shown in Fig. 5. Three distinct subgroups of 4, 3, and 3 patients are

noted in this analysis. To provide additional insight into possible distinguishing features we examined select frequently mutated genes and HPV-16 integration status. HPV-16 integration into the host genome DNA was unique/specific to the second subgroup and present in all three of these tumors (OR 105,  $P = 0.03$ ). Similarly, a trend toward a mutation in *PIK3CA* (OR 25,  $P = 0.07$ ) and subgroup 3 was also observed.

**Xenograft studies**

Targeted sequencing of the xenograft tumor revealed a *PIK3CA* E545K mutation but no other missense mutations in *KRAS*, *NRAS*, *BRAF*, or *EGFR*. Mice were treated with the PI3K inhibitor BYL719 alone, and no difference in mean tumor volume after 35 days was noted between the untreated control group and the experimental group ( $899 \text{ mm}^3$  vs.  $752 \text{ mm}^3$ , respectively;  $P = 0.57$ ; Fig. 6a). However, cetuximab was also tested on the same PDX model, and a significantly lower mean tumor volume was noted for the experimental group relative to the untreated controls after 28 days ( $914 \text{ mm}^3$  vs.  $591 \text{ mm}^3$ , respectively;  $P = 0.04$ ; Fig. 6B).


**Table 2.** Frequency of most commonly occurring mutations in a separate sequencing methodology for 17 SCCA tumors

Gene	Patients with gene mutation in whole-exome analysis (N = 24)	Patients with gene mutation in 263-gene panel (N = 17)	Frequency (%)
MLL3	6	7	32
PIK3CA	7	5	29
MLL2	5	4	22
EP300	3	4	22
TP53	3	5	20
AKT1	2	1	7
ERBB3	2	1	7
PTK2	2	1	7
EGFR	1	1	5
BRAF	2	0	5
FGFR2	0	1	2
KRAS	1	0	2
NRAS	1	0	2

**Discussion**

Here, we report for the first time comprehensive genomic profiling with whole-exome sequencing, copy number assessment, and gene expression profiling specifically for patients with metastatic SCCA. With only cytotoxic chemotherapy agents approved for the treatment of metastatic disease at present, these results provide an important step in the rational design of novel therapies for this understudied malignancy and corroborate results from previous series that characterized the mutation profiling of these tumors using targeted sequencing panels (18, 19).

*PIK3CA* was commonly mutated noted across the entire population associated with both methods of sequencing, present in




**Figure 3.** Median frequency of somatic mutations per megabase of nucleotides analyzed (with interquartile range) for anal cancer and other squamous cell cancer types (**A**) and of the nucleotide substitutions detected for SCCA (**B**).

29% of patients. In addition, this gene was amplified in copy number assessment in greater than two-thirds of cases. Collectively, this gene was aberrant in almost 90% of cases that underwent whole-exome sequencing. The E545K substitution was the most commonly detected mutation of *PIK3CA*. This specific mutation in the helical domain of the PI3K kinase results in constitutive activation of Akt signaling associated with downstream oncogenic activity (21, 22, 26, 27). In previous studies of patients with anal cancer sequenced with more limited gene panels, *PIK3CA* was mutated in approximately one-third of all cases (18, 19), consistent with our findings here. However, *PIK3CA* was amplified in a higher proportion of patients in our study (83%) than in a prior series by Chung and colleagues (<10%). We attribute this discrepancy to a lower threshold for calling a given gene amplified in our analysis ( $\geq 2.5$  copies) relative to that of the other series ( $\geq 6$  copies/gene). Similarly, for squamous cell carcinomas of the head/neck, *PIK3CA* is more frequently mutated in HPV-positive tumors relative to the HPV-negative counterparts (28, 29) and at similar prevalence to our observations here for anal cancer, a disease in which the majority of tumors are HPV-positive. Use of a PI3K inhibitor generated no antitumor response in a *PIK3CA* mutated PDX model of SCCA. While this agent is efficacious in select xenograft models of other solid tumors with *PIK3CA* mutations, the activity of BYL719 as a single agent was less pronounced in a basket trial of patients with *PIK3CA* mutated cancers, with responses occurring in fewer than 20% of cases (30). Based on the relatively high prevalence of *PIK3CA* mutations and amplifications in this disease, further analysis of PI3K inhibitors in *PIK3CA*-mutant models, once available, are warranted to assess the potential application of these agents. Nonetheless, these findings lend further support to the notion that aberrant *PIK3CA* activity is present across the spectrum of HPV-associated malignancies.

Genes important in histone modification were also frequently mutated in our series. For examples, mutations in *MLL2* and *MLL3* were present in 21% and 31% of cases, with the latter being the most commonly mutated gene among all that were assessed across the entire 41 patient cohort. *EP300*, a histone acetyltransferase that modulates transcription of genes critical to physiologic cell proliferation and differentiation including *TP53* (31–33), was mutated in 17% of anal cancers. *MLL2* and *MLL3* belong to the family of histone H3-lysine-4 (H3K4) methyltransferases (34), and trimethylation of *H3K4* promotes physiologic gene expression (35, 36). Mutations in *MLL2* and *MLL3* generate aberrant methylation of *H3K4* and have been associated with oncogenic transformation in preclinical models (37, 38). For example, *MLL3* is important in activation of *TP53* gene expression, and in *TP53* +/- models, loss of *MLL3* activity has been associated with increased cell stress via loss of intact DNA damage repair (39). Similarly, high frequencies of double-stranded DNA breaks have been identified in tumor cells with *MLL2* mutations, and are attributed to decreased expression of the *RNAPOLII* gene encoding for the DNA-proofreading RNA polymerase II (40). *PARP1* overexpression, a poor prognostic biomarker in other solid tumors (41–43) and critical to modulation of chromatin structure (44, 45), was detected in two-thirds of SCCA cases here. Given that HPV oncoprotein E6 suppresses p53 and its downstream DNA repair mechanisms in the predominance of anal cancers (46, 47), these additional mutations and copy number changes responsible for histone/chromatin modulation provide additional insight into defective DNA repair mechanisms as drivers for this malignancy. This notion may be critical for all anal squamous cancers regardless of HPV status, as HPV-negative tumors were also associated in our study with *TP53* mutations, consistent with prior genomic characterizations of other HPV-associated squamous cancers (19, 28).

**Figure 4.** Clinical and pathological characteristics of the 24 patients with metastatic SCCA whose tumors underwent whole-exome sequencing.




Mutated *RRBP1* was a novel finding present in 29% of anal cancers analyzed across the entire exome, and all mutations localized to the same hotspot. This protein functions in post-translational processing of proteins secreted from the endoplasmic reticulum (48) and has been implicated in cell autophagy (49, 50). While these mutations have not been previously described for *RRBP1*, overexpression of this gene has been reported in other solid tumors, including breast and colorectal adenocarcinomas (51, 52). In nonmetastatic colorectal cancer, high expression of *RRBP1* has been described as a poor prognostic biomarker (51). While no effect on metastatic survival was noted in this population of patients with metastatic SCCA based on *RRBP1* mutation status, our findings of this gene warrants further evaluation in future studies for anal cancer.

Mutations in oncogenes critical to MAPK signaling were not routinely detected in the tumors analyzed here. Lack of such mutations has been previously described in anal cancer and is also consistent with other HPV-positive squamous tumors (18, 19). Based on our findings, we do not believe routine testing for mutations in *KRAS*, *NRAS*, or *BRAF* is required, as the results are unlikely to influence clinical decision making in the management of metastatic anal cancer (7). Given that cetuximab, a monoclonal antibody against EGFR and its downstream signaling targets, is approved for surgically unresectable and advanced head/neck

cancers, we tested cetuximab in a PDX model wild-type for *PIK3CA* and for *EGFR*, *KRAS*, *NRAS*, and *BRAF*. While reduction in tumor size was not noted following treatment with BYL719, a significant reduction in tumor volume was seen in tumors treated with cetuximab relative to untreated controls. This finding creates interest in the use of anti-EGFR therapies in *PIK3CA* mutated/ altered SCCA xenograft models. We acknowledge that a single PDX model of SCCA does not capture the entirety of genomic diversity for this malignancy otherwise reported here, and additional models are needed for improved preclinical characterization of the activity of these and other targeted therapies as novel treatment options in the management of metastatic SCCA. Our findings nonetheless provide a rationale for future combination studies involving anti-EGFR therapies in metastatic anal cancers, which often lack activating mutations of MAPK and PI3K/mTOR signaling.

Notably, unlike other solid tumors such as melanoma, renal cell carcinoma, and microsatellite-high colorectal cancer (53, 54), which have demonstrated response to immune checkpoint inhibitors associated with a high underlying mutation burden, our analysis of metastatic anal cancer by whole-exome sequencing did not feature a high mutational load. Indeed, the overall mutation frequency was similar to what has been detected in other HPV-associated squamous cancers. The anti-PD-1 antibody nivolumab



**Figure 5.** Gene expression profiling for 10 cases of metastatic SCCA.


has been reported as an effective therapy for patients with metastatic SCCA from a recent phase II study (55). For a proportion of patients treated with nivolumab, response appeared to be associated with an inflammatory tumor microenvironment characterized by the presence of cytotoxic T cells and a PD-1–PD-L1 axis amenable to blockade by nivolumab. Recently, a case report of a single patient with metastatic SCCA who responded dramatically to anti-PD-1 therapy was found to have a tumor burden/neoantigen load higher (though not statistically significant) to an unpaired population of patients with locoregional SCCA who underwent whole-exome sequencing (56). While further testing is warranted to characterize the interplay between tumor mutation rate and response to immunotherapy in metastatic SCCA, we surmise that the immunogenicity of these tumors is not driven by hypermutated tumors given that our results are consistent with low mutation rates.

In an effort to characterize better these metastatic anal canal cancers, we performed gene expression profiling of ten available frozen tumors. Despite the small number of available specimens, three separate subgroups were identified based on RNA levels of variable genes. *PIK3CA*-mutant tumors appeared to cluster into one distinct group, whereas a second subgroup featured only tumors characterized by integration of HPV-16 DNA into the tumor cell genome. Our findings here are consistent with reported data from head/neck cancers, whereby HPV-negative tumors and *PIK3CA*-mutated tumors clustered into distinct subtypes (57). Detection of HPV DNA into the host genome using this approach has been previously described for HPV-positive cervical and head/neck tumors (58). The differential gene expression patterns, in the background of low mutation burdens, highlight the role of non-mutation aberrations which affect gene expression in a manner relevant to defining subclassifications potentially of this disease. Given the aforementioned genes vital to chromatin remodeling, it

is feasible that epigenetic aberrations may contribute to defining gene expression signatures within this population.

No survival differences or other clinical features were found to be correlated with mutation status in our series. We recognize that our analyses are limited by a relatively small number of tumor samples, a testimony to the sparse number of patients with metastatic anal cancer. In addition, as all patients included in our work had distant metastases, it is possible that their tumors uniformly featured aberrations driving a more aggressive underlying phenotype such that genomic drivers responsible for differential clinical features could not be distinguished among a cohort of only metastatic patients. Future studies comparing genome profiling for patients with early-stage anal cancer, for which the majority of patients will be cured with chemoradiation, are clearly warranted to identify relevant drivers of disease progression or chemoradiation resistance that potentially can be targeted with matched novel therapies.

This series represents the first cohort of patients with metastatic squamous cell cancer of the anal canal to undergo complete exome sequencing. Our findings are strengthened by similar results in an independent cohort of patients whose tumors were sequenced with an alternate methodology. Given the genomic profiling noted by multiple reports, including ours, whole-exome sequencing did not provide additional information for currently available targeted therapies that would inform a clinician on actionable genomic aberrations when considering treatment options for patients with metastatic SCCA. In addition, mutation profiles for our series are consistent with prior data for other HPV-positive malignancies and provide a further rationale for the study of these solid tumors not only by disease site but also by the



**Figure 6.** Growth curves, relative to an untreated control, for a xenograft model established from a patient with metastatic SCCA when treated with a PI3K inhibitor (A) or with an anti-EGFR antibody (B).

responsible underlying biological drivers. Given the emerging role of immunotherapeutic agents in the treatment of metastatic anal cancer, these results provide an important step forward into understanding the relevant drivers for this disease upon which subsequent future clinical trials may be designed.

### Disclosure of Potential Conflicts of Interest

C. Eng reports receiving a commercial research grant from Keryx and Daiichi, has received honoraria from speakers bureau from Genentech, is a consultant/advisory board member for Bayer and Sirtex. No potential conflicts of interest were disclosed by the other authors.

### Authors' Contributions

**Conception and design:** V. Morris, C. Eng

**Development of methodology:** A. Rashid, K. Eterovic, K. Chen, C. Eng

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** V. Morris, W.C. Foo, A. Rashid, K. Eterovic, C. Eng

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** V. Morris, X. Rao, C. Pickering, T. Kim, K. Chen, J. Wang, C. Eng

**Writing, review, and/or revision of the manuscript:** V. Morris, C. Pickering, W.C. Foo, A. Rashid, T. Kim, K. Shaw, C. Eng

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** V. Morris, X. Rao, C. Pickering, K. Shaw, C. Eng

**Study supervision:** V. Morris, C. Eng

### Acknowledgments

The authors would also like to thank Amir Mehdizadeh and Pia Kabalaman for their assistance and support.

### Grant Support

This work was supported by the generous philanthropic contributions to The University of Texas MD Anderson Moon Shots Program, The Zayed Institute for Personalized Cancer Therapy, the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, and an anonymous philanthropic donor.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 2, 2017; revised May 30, 2017; accepted August 2, 2017; published OnlineFirst August 7, 2017.

### References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7–30.
- Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. *Cancer* 2004;101:281–8.
- Bartelink H, Roelofsens F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997;15:2040–9.
- Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol* 1996;14:2527–39.
- Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of Cancer Radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *Int J Radiat Oncol Biol Phys* 2007;68:794–800.
- Eng C. Anal cancer: current and future methodology. *Cancer Invest* 2006;24:535–44.
- Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. *Oncotarget* 2014;5:11133–42.
- Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. *Am J Med* 1989;87:221–4.
- Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, et al. [5-fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer]. *Bull Cancer* 1999;86:861–5.
- Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. *Oncology* 2014;87:125–32.
- Frisch M, Glimelius B, van den Brule AJ, Wohlfahrt J, Meijer CJ, Walboomers JM, et al. Sexually transmitted infection as a cause of anal cancer. *N Engl J Med* 1997;337:1350–8.
- Baricevic I, He X, Chakrabarty B, Oliver AW, Bailey C, Summers J, et al. High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. *Eur J Cancer* 2015;51:776–85.
- De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 2009;124:1626–36.
- Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. *Int J Cancer* 2009;124:2375–83.
- Lukan N, Strobel P, Willer A, Kripp M, Dinter D, Mai S, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. *Oncology* 2009;77:293–9.
- Rogers JE, Ohinata A, Silva NN, Mehdizadeh A, Eng C. Epidermal growth factor receptor inhibition in metastatic anal cancer. *Anticancer Drugs* 2016;27:804–8.
- Vermorken JB, Psyrri A, Mesia R, Peyrade F, Beier F, de Blas B, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. *Ann Oncol* 2014;25:801–7.
- Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. *Oncotarget* 2015;6:43594–604.
- Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. *Ann Oncol* 2016;27:1336–41.
- Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. *Neoplasia* 2011;13:1019–25.
- Chen Y, Yao H, Thompson EJ, Tannir NM, Weinstein JN, Su X. VirusSeq: software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. *Bioinformatics* 2013;29:266–7.
- Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. *Proc Natl Acad Sci U S A* 2006;103:1475–9.
- Center BITGDA. Aggregate Analysis Features (CESC). 2016 doihttp://dx.doi.org/10.7908/C1QC02TZ.
- Center BITGDA. Aggregate Analysis Features (HNSC). 2016 doihttp://dx.doi.org/10.7908/C1C828P8.
- Center BITGDA. Aggregate Analysis Features (LUSC-TP). 2016 doihttp://dx.doi.org/10.7908/C14Q7TDH.
- Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. *Cancer Res* 2005;65:4562–7.
- Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL. PIK3CA mutations in advanced ovarian carcinomas. *Hum Mutat* 2005;25:322.
- Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015;517:576–82.
- Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer Discov* 2013;3:761–9.



30. Gonzalez-Angulo A JD, Argilés G, Schellens JHM, Burris HA, Berlin J, Middleton JR, et al. Safety, pharmacokinetics, and preliminary activity of the  $\alpha$ -specific PI3K inhibitor BYL719: Results from the first-in-human study. *J Clin Oncol* 2013;31:(suppl; abstr 2531).
31. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. *Nat Genet* 2000;24:300–3.
32. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. *Nature* 1997;387:823–7.
33. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. *Cell* 1997;89:1175–84.
34. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. *Mol Cell* 2007;25:15–30.
35. Schneider R, Bannister AJ, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. *Nat Cell Biol* 2004;6:73–7.
36. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, et al. Active genes are tri-methylated at K4 of histone H3. *Nature* 2002;419:407–11.
37. Hu D, Gao X, Morgan MA, Herz HM, Smith ER, Shilatifard A. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. *Mol Cell Biol* 2013;33:4745–54.
38. Herz HM, Mohan M, Garruss AS, Liang K, Takahashi YH, Mickey K, et al. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. *Genes Dev* 2012;26:2604–20.
39. Lee J, Kim DH, Lee S, Yang QH, Lee DK, Lee SK, et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. *Proc Natl Acad Sci U S A* 2009;106:8513–8.
40. Kantidakis T, Saponaro M, Mitter R, Horswell S, Kranz A, Boeing S, et al. Mutation of cancer driver MLL2 results in transcription stress and genome instability. *Genes Dev* 2016;30:408–20.
41. Goncalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. *Breast Cancer Res Treat* 2011;127:273–81.
42. Csete B, Lengyel Z, Kadar Z, Battyani Z. Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor. *Pathol Oncol Res* 2009;15:47–53.
43. Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. *Int J Gynecol Pathol* 2007;26:147–53.
44. Poirier CG, de Murcia G, Jongstra-Bilen J, Niedergang C, Mandel P. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. *Proc Natl Acad Sci U S A* 1982;79:3423–7.
45. Huletsky A, de Murcia G, Muller S, Hengartner M, Menard L, Lamarre D, et al. The effect of poly(ADP-ribosyl)ation on native and H1-depleted chromatin. A role of poly(ADP-ribosyl)ation on core nucleosome structure. *J Biol Chem* 1989;264:8878–86.
46. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. *Science* 1990;248:76–9.
47. Li X, Coffino P. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. *J Virol* 1996;70:4509–16.
48. Savitz AJ, Meyer DI. 180-kD ribosome receptor is essential for both ribosome binding and protein translocation. *J Cell Biol* 1993;120:853–63.
49. Cardoso CM, Groth-Pedersen L, Hoyer-Hansen M, Kirkegaard T, Corcelle E, Andersen JS, et al. Depletion of kinesin 5B affects lysosomal distribution and stability and induces peri-nuclear accumulation of autophagosomes in cancer cells. *PLoS One* 2009;4:e4424.
50. Diefenbach RJ, Diefenbach E, Douglas MW, Cunningham AL. The ribosome receptor, p180, interacts with kinesin heavy chain, KIF5B. *Biochem Biophys Res Commun* 2004;319:987–92.
51. Pan Y, Cao F, Guo A, Chang W, Chen X, Ma W, et al. Endoplasmic reticulum ribosome-binding protein 1, RRBP1, promotes progression of colorectal cancer and predicts an unfavourable prognosis. *Br J Cancer* 2015;113:763–72.
52. Telikicherla D, Marimuthu A, Kashyap MK, Ramachandra YL, Mohan S, Roa JC, et al. Overexpression of ribosome binding protein 1 (RRBP1) in breast cancer. *Clin Proteomics* 2012;9:7.
53. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–54.
54. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015;372:2509–20.
55. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncol* 2017;18:446–53.
56. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, et al. Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. *Clin Cancer Res* 2017;23:3214–22.
57. Zhang YX, Koneva LA, Virani S, Arthur AE, Virani A, Hall PB, et al. Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures. *Clin Cancer Res* 2016;22:4735–45.
58. Chandrani P, Kulkarni V, Iyer P, Upadhyay P, Chaubal R, Das P, et al. NGS-based approach to determine the presence of HPV and their sites of integration in human cancer genome. *Br J Cancer* 2015;112:1958–65.